Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 259

5th Annual Immuno-oncology BD&L and Investment Forum

Posted by fidest press agency su domenica, 26 maggio 2019

Chicago, Illinois Friday, May 31, 2019 10:30 AM Waldorf Astoria Chicago Hotel, immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced that the company will present at the 5th Annual Immuno-oncology BD&L and Investment Forum. Sia Anagnostou, Immunomic’s Senior Director of Corporate Development, will present a company overview and will discuss ITI’s recently expanded, investigational UNiversal Intracellular Targeted Expression (UNITE) platform and its application in immuno-oncology, specifically glioblastoma multiforme (GBM). ITI’s technology platform has the potential to utilize the body’s natural biochemistry to develop a broad immune response and is currently being employed in a Phase II clinical trial as a cancer immunotherapy.

Rispondi

Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo WordPress.com

Stai commentando usando il tuo account WordPress.com. Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

 
%d blogger hanno fatto clic su Mi Piace per questo: